Navigation Links
Sanofi-aventis Announces Second Quarter 2009 Results
Date:7/29/2009

------- ---- -------- Other Vaccines 59 +76.7% 98 +33.8% --------------- ----- ------- ---- -------- TOTAL 712 -0.8% 1,339 +3.7% --------------- ----- ------- ---- --------

* Seasonal and pandemic influenza vaccines

**+3.3% for the quarter and +27.4% for the first half excluding H5N1 vaccines

Second-quarter sales at Sanofi Pasteur MSD (not consolidated by sanofi-aventis), the joint venture with Merck & Co in Europe, were down 14.9% on a reported basis at euro 233 million. Sales of Gardasil((R)), for the prevention of papillomavirus infections (a major cause of cervical cancer), were down 27.4% at euro 108 million. This decrease was due to extensive catch-up campaigns in the prior year. Excluding Gardasil((R)), sales of the rest of the portfolio were stable. First-half sales at Sanofi Pasteur MSD were down 11.8% on a reported basis at euro 487 million.

Net sales by geographic region

                                 Change at            Change at
                                 constant             constant
                        Q2 2009  exchange    H1 2009   exchange
    Millions of euros net sales   rates     net sales   rates
    ----------------- ---------  --------   ---------- --------
    Europe               3,079      +4.6%      6,027     +1.8%
    ---------           ------    ------       -----     ----
     of which
      Eastern
      Europe               439     +37.5%        799    +27.0%
    ---------           ------    ------       -----     ----
    United States        2,438      +5.4%       4,733    -0.1%
    -------------       ------    ------       -----     ----
    Other Countries      1,921     +11.2%       3,785    +9.4%
    ---------------      -----     -
'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related biology technology :

1. Sanofi-aventis Announces Settlement of Average Wholesale Price Civil Suits With the U.S. Department of Justice Relating to Anzemet(R)
2. Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
3. Sanofi-aventis SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award
4. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
5. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
6. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
7. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
8. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
9. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 2014 HealthTronics, Inc ., ... radiology products and services, announced that a poster ... cryoablation) versus external beam radiotherapy (EBRT) is being ... Urological Association (MAAUA) Annual Meeting in Baltimore, Maryland ... of Cryosurgery and External Beam Radiation as Treatments ...
(Date:9/18/2014)... DALLAS , Sept. 18, 2014 /PRNewswire-iReach/ -- ... and China Acetic Acid Industry" and "2014 Deep ... Industry" reports to its research database. ... 2014 Deep Research Report on Global and China ... research report on China ...
(Date:9/18/2014)... , Sept. 18, 2014  Health Enhancement Products, Inc. ... investigating early-stage algae bioactive compounds and metabolic processes, is pleased ... company,s board of directors. Ms. Nola E. Masterson , ... advisor joined the board effective September 17, 2014. ... agree to join our board," states Andrew Dahl , ...
(Date:9/18/2014)... Texas (PRWEB) September 18, 2014 ... Chancellor John Sharp, Texas A&M Health Science Center ... U.S. Department of Health and Human Services (HHS), ... dedicated a national pandemic influenza vaccine manufacturing facility ... as an anchor for the Texas A&M Biocorridor ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4Health Enhancement Announces New Board Member In Advance Of Annual Shareholder Meeting 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4
... 2011 Insmed Incorporated (Nasdaq: INSMD), a biopharmaceutical company, ... (IND) to conduct a pivotal Phase 3 clinical trial ... nontuberculous mycobacteria (NTM) lung infections has been cleared by ... In 2010, Insmed initially submitted a regulatory filing ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... pivotal trial of pixantrone for the treatment of relapsed/refractory ... now open to patient enrollment. The trial, referred to ... a combination of pixantrone plus rituximab to a combination ...
... Driving value for customers is critical to organizational success across ... customer and an organization, there has to be an integrated ... succeed in the marketplace. Chris Bogan, CEO ... in this month,s special issue of PharmaVoice that the state ...
Cached Biology Technology:Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 2Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 3Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 4Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication 5Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 2Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 3Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma 4Best Practices, LLC Showcases Its Expertise in Customer Relationship Management 2
(Date:9/18/2014)... that can operate inside the bore of an MRI ... biomedical research partnership program at Brigham and Women,s Hospital ... robot, in conjunction with real-time MRI images, can make ... less discomforting for the patient. The novel system also ... greater precision. , Developed by a team of robotics ...
(Date:9/18/2014)... Americans to undertake jaunts into the countryside each year could ... a century, according to new research. , Climate change could ... States as summer temperatures linger later into the year, Princeton ... Biogeography . For instance, the paper birch a popular ... could change color one to three weeks later by ...
(Date:9/18/2014)... -- Arizona turned its newborn screening program into a model ... earning it the first-ever Newborn Screening Quality Award from the ... Will Humble, M.P.H., Arizona,s Department of Health Services director, with ... established a policy of full transparency for the length of ... to the lab for analysis, and set a target of ...
Breaking Biology News(10 mins):Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... has declined steadily in the last three decades. Although ... groups have shown some improvement, according to a recent ... the American Association for Cancer Research. "Our ... treatment, have resulted in profound gains, but these gains ...
... Barbara, Calif.) Scientists at UC Santa Barbara have found ... findings are published online in this week,s issue of the ... species differences in how they use the environment are key ... around us, but the importance of such niches have never ...
... the human brain reshapes itself to store this newfound knowledge. ... does that capacity to adapt reflect our risk for Alzheimer,s ... lives? Dr. Yaniv Assaf of Tel Aviv University,s Department ... effect of memory on brain structure. "With a specific MRI ...
Cached Biology News:Cancer mortality rates experience steady decline 2Scientists demonstrate importance of niche differences in biodiversity 2A window into the brain 2
... 2D polyacrylamide gel electrophoresis (2D-PAGE) with biological ... core technology platform for proteomic analysis. 2D-PAGE ... samples limited only in the dynamic range ... proteins. Quantitative image based analysis of separated ...
... 177 amino acid polypeptide sequence corresponding to ... Produced by activation of a recombinant ... coli periplasm. SPECIFIC ACTIVITY:The specific activity ... mU/mg, where 1 U is the activity ...
Human interferon-beta (IFN-beta). Recognizes amino acids 30-47 of IFN-beta. No cross-reactivity with Human IFN-alpha or IFN-gamma....
Acetate Plate Sealers 100/Box...
Biology Products: